UroGen Pharma Ltd. Banner Image

UroGen Pharma Ltd. has reached its limit for free report views

Work for UroGen Pharma Ltd.? Upgrade Your Profile and unlock all your annual reports.

UroGen Pharma Ltd.

  • Ticker URGN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
UroGen Pharma Ltd. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained releaseMore technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved product, Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ with operations in Israel.
4.7 / 5.0 (130)

UroGen Pharma Ltd. reports have an aggregate usefulness score of 4.7 based on 130 reviews.

UroGen Pharma Ltd.

Most Recent Annual Report

UroGen Pharma Ltd.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. UroGen Pharma Ltd. has reached its limit for free report views.

Older/Archived Annual Reports

UroGen Pharma Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!